Orbital Therapeutics is a technology company.
Orbital Therapeutics has raised $270.0M across 1 funding round.
Key people at Orbital Therapeutics.
Orbital Therapeutics has raised $270.0M in total across 1 funding round.
Orbital Therapeutics has raised $270.0M in total across 1 funding round.
Orbital Therapeutics's investors include Andreessen Horowitz, ARCH Venture Partners, Nextech Invest, Section 32, Versant Ventures.
Key people at Orbital Therapeutics.
Orbital Therapeutics is a biotechnology company developing RNA-based medicines (excluding RNAi therapeutics) to treat human diseases in innovative ways, with an initial focus on vaccines, immunomodulation, protein replacement, and regenerative medicine.[1][2][3] Headquartered in Cambridge, Massachusetts, and founded in 2022, the company employs around 55 people and has raised $270 million in funding, building a state-of-the-art platform that integrates RNA discovery, development, delivery technologies, data science, and automation.[1][5] It serves patients with unmet needs in immunology and beyond by creating therapies that offer precision, durability, and expanded tissue targeting, positioning it as a next-generation player in RNA therapeutics.[2][4]
Orbital Therapeutics launched in September 2022, founded by experts in genetic medicine, RNA development, and delivery, bringing together scientific pioneers, drug developers, and biopharma executives.[1][2] The idea emerged from recognizing RNA's revolutionary potential—seen in mRNA vaccines—while addressing limitations in durability, delivery, and application breadth, leading to a comprehensive platform excluding RNAi.[2][4] A pivotal moment was its strategic partnership with Beam Therapeutics, granting mutual access to RNA and non-viral delivery technologies: Orbital for vaccines and therapeutic proteins, Beam for gene editing.[2][4] Early traction included $270 million in funding and leadership appointments, such as Ron Philip as CEO, a veteran biopharma leader.[5]
Orbital rides the RNA therapeutics wave, accelerated by mRNA COVID-19 vaccines, expanding into durable, programmable treatments for prevalent and rare diseases amid growing demand for immunomodulators and regenerative options.[2][4] Timing is ideal as RNA science matures—post-pandemic validation meets advances in delivery and automation—while market forces like aging populations and immunotherapy needs favor platforms like Orbital's.[1][3] It influences the ecosystem by licensing tech (e.g., with Beam), investing in platform growth, and attracting top talent, potentially broadening RNA's impact beyond gene silencing to protein production and tissue repair.[2][4][6]
Orbital is poised to advance its pipeline toward clinical trials, leveraging its platform for first-in-class RNA medicines in immunology and beyond, with Bristol Myers Squibb connections signaling potential big-pharma alliances.[6] Trends like AI-driven drug design, non-viral delivery innovations, and regulatory tailwinds for RNA will shape its path, amplifying influence as it scales from 55 employees to portfolio expansion. This positions Orbital to transform global health, fulfilling its launch vision of unleashing RNA's full potential.[2][3]
Orbital Therapeutics has raised $270.0M across 1 funding round. Most recently, it raised $270.0M Series A in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $270.0M Series A | Andreessen Horowitz, ARCH Venture Partners, Nextech Invest, Section 32, Versant Ventures |
